NT Pharma issues 274.75 million consideration shares for acquisition, expanding share base by 40.75%

Bulletin Express

Mar 25

China NT Pharma Group Company Limited (NT Pharma) has allotted 274.75 million new ordinary shares on 25 March 2026 to eight vendors as full consideration for acquiring 100% equity interests in designated target companies.

• Scale of issuance: The new shares represent 40.75% of NT Pharma’s pre-transaction issued share capital.

• Issue terms: Shares were issued at HKD 0.45 each, valuing the consideration at approximately HKD 123.64 million.

• Share capital impact: The company’s issued shares rose from 674.25 million to 949.00 million after the transaction, with no treasury shares outstanding. All newly issued shares rank pari passu with existing shares.

• Authorisation: The allotment was made under a specific mandate approved by shareholders at the extraordinary general meeting held on 15 January 2026 and confirmed by the board to comply with all applicable Hong Kong listing rules and regulatory requirements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1146644823"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1146644823\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1146644823?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 19:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1146644823","market":"hk","top_or_hot":-1,"title":"NT Pharma issues 274.75 million consideration shares for acquisition, expanding share base by 40.75%","media":"Bulletin Express","content":"<p>China NT Pharma Group Company Limited (NT Pharma) has allotted 274.75 million new ordinary shares on 25 March 2026 to eight vendors as full consideration for acquiring 100% equity interests in designated target companies.</p>\n<p>• Scale of issuance: The new shares represent 40.75% of NT Pharma’s pre-transaction issued share capital.</p>\n<p>• Issue terms: Shares were issued at HKD 0.45 each, valuing the consideration at approximately HKD 123.64 million.</p>\n<p>• Share capital impact: The company’s issued shares rose from 674.25 million to 949.00 million after the transaction, with no treasury shares outstanding. All newly issued shares rank pari passu with existing shares.</p>\n<p>• Authorisation: The allotment was made under a specific mandate approved by shareholders at the extraordinary general meeting held on 15 January 2026 and confirmed by the board to comply with all applicable Hong Kong listing rules and regulatory requirements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NT Pharma issues 274.75 million consideration shares for acquisition, expanding share base by 40.75%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNT Pharma issues 274.75 million consideration shares for acquisition, expanding share base by 40.75%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-25 19:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China NT Pharma Group Company Limited (NT Pharma) has allotted 274.75 million new ordinary shares on 25 March 2026 to eight vendors as full consideration for acquiring 100% equity interests in designated target companies.</p>\n<p>• Scale of issuance: The new shares represent 40.75% of NT Pharma’s pre-transaction issued share capital.</p>\n<p>• Issue terms: Shares were issued at HKD 0.45 each, valuing the consideration at approximately HKD 123.64 million.</p>\n<p>• Share capital impact: The company’s issued shares rose from 674.25 million to 949.00 million after the transaction, with no treasury shares outstanding. All newly issued shares rank pari passu with existing shares.</p>\n<p>• Authorisation: The allotment was made under a specific mandate approved by shareholders at the extraordinary general meeting held on 15 January 2026 and confirmed by the board to comply with all applicable Hong Kong listing rules and regulatory requirements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01011","symbol_name":"泰凌医药","start_time":0,"source_url":"","article_id":"1146644823","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1146644823","pubTimestamp":1774438924,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"China NT Pharma Group Company Limited (NT Pharma) has allotted 274.75 million new ordinary shares on 25 March 2026 to eight vendors as full consideration for acquiring 100% equity interests in...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01011":"泰凌医药"},"translate_title":"泰凌医药发行2.7475亿股收购代价股扩大40.75%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01011":1},"content_text":"China NT Pharma Group Company Limited (NT Pharma) has allotted 274.75 million new ordinary shares on 25 March 2026 to eight vendors as full consideration for acquiring 100% equity interests in designated target companies.\n• Scale of issuance: The new shares represent 40.75% of NT Pharma’s pre-transaction issued share capital.\n• Issue terms: Shares were issued at HKD 0.45 each, valuing the consideration at approximately HKD 123.64 million.\n• Share capital impact: The company’s issued shares rose from 674.25 million to 949.00 million after the transaction, with no treasury shares outstanding. All newly issued shares rank pari passu with existing shares.\n• Authorisation: The allotment was made under a specific mandate approved by shareholders at the extraordinary general meeting held on 15 January 2026 and confirmed by the board to comply with all applicable Hong Kong listing rules and regulatory requirements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"shareholding,merge,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}